Roche scrutinized by UK watchdog over ‘misleading’ Rozlytrek promotional website

The UK’s Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty (PM­C­PA) has ruled that a Roche web­page for its can­cer med­ica­tion Ro­z­lytrek mis­led health­care pro­fes­sion­als.

The al­le­ga­tions stemmed from an anony­mous com­plaint filed by a self-pro­claimed health pro­fes­sion­al who ar­gued that Roche’s re­sources web­site left out im­por­tant in­for­ma­tion around po­ten­tial dose re­duc­tions and dis­con­tin­u­a­tions for cer­tain pa­tients be­ing mon­i­tored on the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.